(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Pramod P. Reddy, MD Director, Division of Pediatric Urology
is a pediatric urologist studying the molecular regulation of bladder organogenesis using a Xenopus animal model, tissue engineering strategies for bladder substitution/replacement and epigenetic changes in bladder outlet obstruction. He conducts several clinic outcome studies on neurogenic detrusor instability, overactive bladder and the use of catheters in children with neurogenic bladders.
Director, Division of Pediatric Urology
Professor, UC Department of Pediatrics
Kidney stones; ESWL; genitourinary surgery; clinical trials
MBBS: Nagarjuna University, Guntur, India, 1990.
Residency: Albany Medical Center, Albany, NY.
Fellowship: The Hospital For Sick Children, Toronto, ON, Canada.
Certification: American Board of Urology, 2001.
Reddy PP, Defoor WR. Ureteroscopy: The standard of care in the management of upper tract urolithiasis in children. Indian J Urol. 2010 Oct;26(4):555-63.
Ivancić V, Defoor W, Jackson E, Alam S, Minevich E, Reddy P, Sheldon C. Progression of renal insufficiency in children and adolescents with neuropathic bladder is not accelerated by lower urinary tract reconstruction. J Urol. 2010 Oct;184(4 Suppl):1768-74.
DeFoor WR, Jackson E, Minevich E, Caillat A, Reddy P, Sheldon C, Asplin J. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010 Jul;76(1):242-5.
Traxel E, DeFoor W, Reddy P, Sheldon C, Minevich E. Risk factors for urinary tract infection after dextranomer/hyaluronic acid endoscopic injection. J Urol. 2009 Oct;182(4 Suppl):1708-12.
DeFoor WR, Heshmat S, Minevich E, Reddy P, Koyle M, Sheldon C. Long-term outcomes of the neobladder in pediatric continent urinary reconstruction. J Urol. 2009 Jun;181(6):2689-93; discussion 2693-4.
Reddy PP, Borgstein NG, Nijman RJ, Ellsworth PI. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J Pediatr Urol. 2008 Dec;4(6):428-33.
DeFoor W, Clark C, Jackson E, Reddy P, Minevich E, Sheldon C. Risk factors for end stage renal disease in children with posterior urethral valves. J Urol. 2008 Oct;180(4 Suppl):1705-8; discussion 1708.
Heshmat S, DeFoor W, Minevich E, Reddy P, Reeves D, Sheldon C. Use of customized MIC-KEY gastrostomy button for management of MACE stomal complications. Urology. 2008 Nov;72(5):1026-9.
DeFoor W, Minevich E, Jackson E, Reddy P, Clark C, Sheldon C, Asplin J. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol. 2008 Jun;179(6):2369-72.
Reddy PP. Recent advances in pediatric uroradiology. Indian J Urol. 2007 Oct;23(4):390-402.
William Robert DeFoor Jr., MD, MPH Director, Clinical Research
is a pediatric urologist conducting a multi-institutional clinical trial to assess outcomes in vesico-ureteral reflux. Other studies include outcomes in neurogenic bladder (NGB), urinary biomarkers in ureteropelvic junction obstruction, complications of clean intermittent catheterization, urinary metabolic evaluations in bariatric patients, and UTI prevention with gentamicin bladder irrigations.
Director, Clinical Research
Associate Professor, UC Department of Surgery
Complex genitourinary reconstruction; clinical outcomes research; clinical trials; urolithiasis; uro-oncology; laparoscopic-assisted; robotic-assisted surgery; vesicoureteral reflux
BS: Georgia Institute of Technology, Atlanta, GA, 1991.
Fulbright Fellowship: Universite' Rene' Descartes, Paris, France, 1992.
MD: University of Kentucky, Lexington, KY, 1996.
Residency: Medical University of South Carolina, Charleston, SC, 2001.
Fellowship: Cincinnati Children's Hospital, Cincinnati, OH, 2003.
MPH: Harvard University, Boston, Massachusetts, School of Public Health, 2005.
DeFoor, WR, et al. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010 Jul;76(1):242-5.
DeFoor WR, et al. Long-Term Outcomes of the Neobladder in Pediatric Continent Urinary Reconstruction. J Urol. 2009;181:2689-94.
Traxel E, DeFoor WR, et al. Multivariate analysis of risk factors for urinary tract infections after endoscopic injection of dextranomer-hyaluronic acid. J Urol. 2009;182 (4 Suppl): 1708-12.
DeFoor WR, Tobias N. Simple behavioral modification may be effective first-line treatment in resolution of nocturnal enuresis. J Pediatrics. 2009;155(5):760.
Heshmat S, DeFoor WR, et al. The use of customized Mic-Key gastrostomy button for the management of the MACE stomal complications. Urology. 2008;72(5):1026-9.
DeFoor WR, et al. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol. 2008;179(6):2369-72.
DeFoor WR, et al. Risk factors for end stage renal disease in children with posterior urethral valves. J Urol. 2008;180(4 Suppl):1705-8; discussion 1708.
Joo-Seop Park, PhD
is interested in understanding how progenitor cells maintain their multi-potent status and how they differentiate into different types of cells during organogenesis of the mammalian kidney and bladder. His lab studies transcriptional and epigenetic controls of cis-regulatory modules that act downstream of various signaling pathways.
Visit the Park Lab.
Assistant Professor, UC Department of Surgery
Molecular biology; genetics.
Joo-Seop Park, PhD, is an assistant professor in the Divisions of Pediatric Urology and Developmental Biology at Cincinnati Children's Hospital Medical Center. He received his bachelor's in pharmacy from Seoul National University in Seoul, South Korea. He subsequently studied the regulation of gene transcription with Dr. Jeffrey W. Roberts at Cornell University in Ithaca, NY where he obtained his doctorate in molecular biology and genetics in 2004. Dr. Park then went on to postdoctoral training with Dr. Andrew P. McMahon at Harvard University where he was awarded fellowships from the National Kidney Foundation and the Charles King Trust to study mammalian kidney development.
Dr. Park is interested in understanding how progenitor cells maintain their multi-potent status and how they differentiate into different types of cells during organogenesis of the mammalian kidney and bladder. His lab studies transcriptional and epigenetic controls of cis-regulatory modules that act downstream of various signaling pathways.
Brunskill EW, Park JS, Chung E, Chen F, Magella B, Potter SS. Single cell dissection of early kidney development: multilineage priming. Development. 2014;141, 3093-3101.
Xu J, Liu H, Park JS, Lan Y, Jiang R. Osr1 acts downstream of and interacts synergistically with Six2 to maintain nephron progenitor cells during kidney organogenesis. Development. 2014;141, 1442-1452.
Wang J, Park JS, Wei Y, Rajurkar M, Cotton JL, Fan Q, Lewis BC, Ji H, Mao J. TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPalpha function. Mol Cell. 2013;51, 211-225.
Park JS, Ma W, O'Brien LL, Chung E, Guo JJ, Cheng JG, Valerius MT, McMahon JA, Wong WH, McMahon AP. Six2 and Wnt regulate self-renewal and commitment of nephron progenitors through shared gene regulatory networks. Dev Cell. 2012;23, 637-651.
Park JS, Valerius MT, McMahon AP. Wnt/beta-catenin signaling regulates nephron induction during mouse kidney development. Development. 2007;134, 2533-2539.
Park JS, Roberts JW. Role of DNA bubble rewinding in enzymatic transcription termination. Proc Natl Acad Sci U S A. 2006;103, 4870-4875.
Carroll TJ, Park JS, Hayashi S, Majumdar A, McMahon AP. Wnt9b plays a central role in the regulation of mesenchymal to epithelial transitions underlying organogenesis of the mammalian urogenital system. Developmental cell. 2005;9, 283-292.
Roberts J, Park, JS. Mfd, the bacterial transcription repair coupling factor: translocation, repair and termination. Current opinion in microbiology. 2004;7, 120-125.
Park JS, Marr MT, Roberts JW. E. coli Transcription repair coupling factor (Mfd protein) rescues arrested complexes by promoting forward translocation. Cell. 2002;109, 757-767.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center